-
Synopsis: Clostridium difficile-associated disease (CDAD) is increasing in incidence and severity, and is appearing in patients even in the absence of recent hospitalization or antimicrobial use.
-
Greenfield RH. Short but sweetchocolate and CVD. Altern Med Alert 2006;9(2):24.
-
Shalts E. Homeopathy: A brief overview with examples. Altern Med Alert 2006;9(2):17-24.
-
Kiefer D. Vitamin D supplementation and bone health. Altern Med Alert 2006;9(2):13-16.
-
-
-
The US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends efavirenz (EFV) as part of the preferred non-nucleoside reverse transcriptase inhibitor-based regimen for HIV patients.
-
This interesting paper from Groopman's laboratory at Beth Israel in Boston, reports the results of some elegant experiments designed to elucidate potential mechanisms, accounting for the innocent bystander hepatocyte apoptosis previously observed as a result of binding of HCV and HIV proteins.
-
Lagrotteria and colleagues enrolled 39 inpatients with a primary episode of Clostridium difficile-associated diarrhea (CDAD) to receive treatment for 10 days with either metronidazole (MET) alone or together with rifampin (RIF).
-
Darunavir (known during development as TMC114 and given the proprietary name, PREZISTA-TM) was approved by FDA on June 23, 2006, for use in combination with other antiretroviral agents for the treatment of HIV infection in adults.